title: Perspectives in the development of novel treatment approaches.
authors.affiliation: University of Texas MD Anderson Cancer Center, USA.
authors.forename: James C
authors.initials: JC
authors.lastname: Yao
authors.forename: Laura
authors.initials: L
authors.lastname: Catena
authors.forename: Annamaria
authors.initials: A
authors.lastname: Colao
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paganelli
mesh_terms: D000182:ACTH Syndrome, Ectopic / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D000068258:Bevacizumab; D001786:Blood Glucose / Q000187:drug effects; D017322:Clinical Trials, Phase II as Topic; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D043169:Endostatins / Q000627:therapeutic use; D000068338:Everolimus; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D007340:Insulinoma / Q000097:blood / Q000188:drug therapy; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D015337:Multicenter Studies as Topic; D018358:Neuroendocrine Tumors / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011880:Radiotherapy Planning, Computer-Assisted; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000077210:Sunitinib; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D018492:Dopamine Antagonists; D043169:Endostatins; D007166:Immunosuppressive Agents; D007211:Indoles; D009942:Organometallic Compounds; D010456:Peptides, Cyclic; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; C060347:lanreotide; D000068258:Bevacizumab; D013004:Somatostatin; C401859:temsirolimus; D000068877:Imatinib Mesylate; D000068338:Everolimus; C447941:lutetium Lu 177 dotatate; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D015282:Octreotide; C106246:Edotreotide; D000077210:Sunitinib; D020123:Sirolimus